DOCSLIB.ORG

National Institute on Drug Abuse Division of Research I! 5600 Fishers Lane Rockville, Maryland 20857 II for Sale by the Stlperinten(Lent of Documents, U.S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National Institute on Drug Abuse Division of Research I! 5600 Fishers Lane Rockville, Maryland 20857 II for Sale by the Stlperinten(Lent of Documents, U.S If you have issues viewing or accessing this file contact us at NCJRS.gov. National institute on Drug Abuse ,/1 f "--1 MONOGRAPH SERIES P @bl® ss De esdesee o o~ ~he •dings.nnua0 Scientific Needing i© ~,mmi~ee on Prob0ems Dependence, Inc. i00760-i007i I~ ~) NationalU.S.Department Institute ofJustice This documenl has been reproduced exactly as received from the person or organization originaling it. Points of vew o opinions s[ated in this documenl are those OI the authors and do not necessarily II represenl lhe official position or policies of the National Institute of Justice. Permission Io reproduce this col=,y,~ malerial has been granled by Public Domain/US Department of Health and Human Services Io Ihe National Criminal Justice Reference $e~ice (NCJR$). Ill DEPARTMENTOF HEALTHkN0 Further reproduction outside of fhe NCJRS system requires permis- le sion Of the ~ owner. q i I I ! I I ! I I .! I i i I I I | problems of~Drug Depe~6ence, 1980 | i Proceedings of the 42nd Annual Scientific Meeting, I The Committee on Problems of Drug Dependence, Inc. J I Editor: Louis S. Harris, Ph.D. II II II NIDA Research Monograph 34 February 1981 II I DEPARTMENTOF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research I! 5600 Fishers Lane Rockville, Maryland 20857 II For sale by the Stlperinten(lent of Documents, U.S. Government Printing Office 'tVnshington, I).C, 20402 I II The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of--- state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. - - Addiction Research Foundation Polo Alto, Colifornio -~ Jerome Jaffe, M.D. College of Physicions ond Surgeons - Columbia University, New York Reese T. Jones, M.D. Longley Porter Neuropsychiotric Institute University of Colifornio Son Francisco. California William McGIothlin, Ph.D. Depodment of Psychology. UCLA Los Angeles. California Jack Mendelson, M.D. Alcohol ond Drug Abuse Reseorch Center Horvo~d Medical School McLeon Hospital Belmont. Mossochusetts Helen Nowlis, Ph.D. / Office of;Drug Educotion. DHitS Washington, D.C. Lee Robins, Ph.D. Woshington University School of Medicine St. Louis, Missouri NIDA Research Monograph series William Pollin, M.D. DIRECTOR, NIDA Marvin Snyder, Ph.D. DIRECTOR, DIVISION OF RESEARCH, NIDA Robert C. Petersen, Ph.D. EDITOR-IN-CHIEF Eleanor W. Waldrop MANAGING EDITOR Porklawn Building. 5600 Fishers Lone, Rc~kville. Maryland 20857 Iw, I Problems of Drug Dependence, I ~80 i Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, - ' Inc. ~BERS, C(IX~fITrEE ON PROBLI~4S OF DRUG DEPEND~CE, INC. Dr. Joseph Cochin, Chairman Dr. Joseph Brady I Dr. Troy Duster Dr. Charles Corodetzky Dr. Louis Harris Dr. Theresa Marwood Dr. Arthur Jacobson I Dr. Jerome Jaffe Dr. Arthur Keats Dr. Harold Kalant Dr. Everette May I Dr. Jack Mandelson Dr. C.R. Schuster Dr. Henry Swain I E~CUTIVE SECRETARY Dr. Leo Hollister I M[~ERS t BOARDOF DIRECTORS Dr. E.L. Way, Chairman Am. Soc. Pharmacol. Exptl. ?her. Dr. D.X. Freedman I Am. Psychiatric Assn. Dr. K.F. Killam Am. Coil. Neuropsythopharmacol t Dr. Everette May I Am. Chemical Society Dr. Edward C. Senay Am. Medical Assn. Dr. Beny J. Primm I Nat'l Medical Assn. Dr. James Woods Am. Psychological Assn. Dr. Raymond W. Houde I Am. Soc. Clin. Pharmacol. Ther. I I Mt94BERSt PROGRAM CONI~4ITTEE Dr. Louis S. Harris, Chairman I Dr. Everette L. May Mrs. Rena Holliday MI~IBERS~ C,(3M'4ITI'EEON ARRANGEMENTS I Dr. Joseph Cochin Dr. Louis S. Harris Dr. Jack Mendelson I I I I I I I I I I I I I I m ACKNO~MENT The papers in this monograph were presented or read by title at the 42nd Annual Scientific Meeting of I the Committee on Problems of Drug Dependence, Inc., in Hyarmis, Nassachusetts, on June 16-19, 1980. Opinions expressed in the papers are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug I Abuse; Alcohol, Drug Abuse, and Mental Health Admin- istration; Public Health Service; or the Department I of Health and Htmmn Services. The National Institute on Drug Abuse has obtained permission from the copyright holder to print ! material, as noted, on page 69. Further repro- doction of this material without specific permission of the copyright holder is prohibited. All other material except quoted passages from copyrighted sources is in the public domain and may be repro- I duced without permission. Citation as to source is appreciated. The United States Government does not endorse or I favor any specific commercial product or commodity. Trade or proprietary names appearing in this publi- cation are used only because they are considered ! essential in the context of the studies reported herein. m Library of Congress catalog card nt~ber 81-600016 ll~ publication nt~nber (AIN) 81-i058 Printed 1981 I NIDA Research .Vonographs are indexed in the Index Medicus. They are selectively included in the coverage of Bioseienees Information Service, Chemical I Abstracts, Current Contents, Psychological Abstracts, and Psychopharmacology Abstracts, m i m m I CONTRIBUTING FIRMS r 1979-80 The following firms have supported the work of the Committee on I Problems of Drug Dependence, Inc., through contributions during the previous fiscal year. I Abbott Laboratories American Hoechs t C.H. Boehringer Sohn Bristol Laboratories I Burroughs Wellcome ~ Company f~emie Linz AG Clin-Midy of America, Inc. Eli Lilly and Company I Endo Laboratories, Inc. Hoffman- LaRoche, Inc. ICI Americas) Inc. l Knoll Pharmaceutical Company Lederle Laboratories McNeil Laboratories Mead-Johnson Merck) Sharpe) and Dohme Merrell-National Laboratories) Inc. I Miles Laboratories) Inc. Ortho Pharsaceut icals Pennwal t Corporation Pfizer Central Research I Reckitt ~ Coleman Products, Ltd. A.H. Robins Company Sando z Ltd. Sando z-Wander p Inc. I G.D. Searle Company SISA) Inc. Smith, Kline ~ French E.R. Squibb ~ Sons, Inc. I Sterling Drug, Inc. The Upjohn Company USV Pharmaceutical Corp. Wyeth Laboratories I I I I vl I I I I I Foreword I In each year's calendar of scientific events related to drug abuse, the Annual Scientific Meeting of the Conmittee on Problems of Drug Dependence, Inc., is an occasion of outstanding importance. I The membership of the CPDD represents a broad spectrum of exper- tise that includes pharmacology, clinical medicine, psychiatry, , public health, chemistry, and the social sciences. The Committee maintains liaison with Coverament regulatory and research agencies, I with the pharmaceutical industry, with national and international asencies that are interested in drug dependence and abuse, and with educational and treatment facilities. I The proceedings of each annual CPDD meeting are a comprehensive gathering of reports on current research in all aspects of drug abuse and drug dependence. Topics presented in Problems of Drug Dependence~ 1980 include the effects of drugs on the central ner- I vous system, their pharmacological action, biological disposition, safety, abuse potential, and clinical usefulness. Annual progress reports of NIDA-supported dependence studies of new compounds are included, in addition to the 40 papers presented and 6 papers read by title at the 42nd Annual Scientific Meeting in Hyannis, Massa- I chusetts, on June 18-20, 1980. There is also an extensive index. Some of the papers have been condensed by the authors to meet space limitations of this volume. I In the belief that readers with widely diverse interests will find this timely review of value, the National Institute on Drug Abuse is pleased, for the second year, to publish in its Research ~ono- graph series the Proceedings of the Annual Scientific Meeting of I the Committee on Problems of Drug Dependence, Inc. William Pollin, M.D. Director I National Institute on Drug Abuse i I I vii I I I l I I I I I I I I I I II II II I I I I, I I I Papers Presented at the 42nd Annual I CPDD Meeting I I I I I I i I I ! I I I I I I I I I I I I i I II II ! Dynorphin I Nathan B. Eddy Memorial Award Lecture I A. Goldstein I It is indeed a very great hGnor to be chosen as recipient of the 1980 Nathan B. Eddy Memorial Award. Dr. Eddy was one of the truly great picneers in the field of opiate research and, in more ways i than one, my own research o~s inspiratice to what he contributed to our field. I have stood here so often before, ce the platform at previous meetings of CPDD, presenting SaTe research finding, while Dr. Eddy -- right there in the second row -- listened and took notes. I can re~emher if cne said anything at all that lacked I sufficient experirmntal evidence or was too speculative, he would look up suddenly, then scribble more vigorously in his notebook. ~nd afterwards, in corridor discussion, cee would have to defend cne's ccnclusices against his &harp and perceptive criticisr~. It has been said that if we accomplish anything at all in science, I it is tecause we can stand Gn the sh(m/lders of giants. Besides Dr. Eddy, there have been other giants in our field -- some of them in , this room today -- ups% whose shoulders I was lucky enough to stand.
Load more

Recommended publications
  • Alternative Formats If You Require This Document in an Alternative Format, Please Contact: [email protected]
    University of Bath PHD The extraction and chemistry of the metabolites of Mimosa tenuiflora and Papaver somniferum Ninan, Aleyamma Award date: 1990 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 23. Sep. 2021 THE EXTRACTION AND CHEMISTRY OF THE METABOLITES OF MIMOSA TENUIFLORA AND PAP AVER SOMNIFERUM. submitted by ALEYAMMA NINAN for the degree of Doctor of Philosophy of the University of Bath 1990 Attention is drawn to the fact that the copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without prior consent of the author.
    [Show full text]
  • The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans
    >+'è ,'i5 1. The Disposition of Morphine and its 3- and 6- Glucuronide Metabolites in Humans and Sheep A Thesis submitted in Fulfilment of the Requirements for the Degree of Doctor of Philosophy in Science at the University of Adelaide Robert W. Milne B.Pharm.(Hons), M.Sc. Department of Clinical and Experimental Pharmacology University of Adelaide August 1994 Ar,-,..u i.'..t itttlí I Corrigenda Page 4 The paragraph at the top of the page should be relocated to inimediatèly follow the section heading "1.2 Chemistry" on page 3" Page 42 (lines 2,5 and/) "a1-acid glycoProtein" should read "cr1-acid glycoprotein". Page 90 In the footnote "Amoxicillin" and "Haemacell" should read "Amoxycillin" and "Haemaccel", respectively. Page I 13 (tine -l l) "supernate!' should read "supernatant". ' '(j- Page I 15 (line -9) "supernate" should read "supernatalït1-. Page 135 To the unfinished sentence at the bottom of the page should be added "appears to be responsible for the formation of M3G, but its relative importance remains unknown. It was also proposed that morphine is involved in an enterohepatic cycle." Page 144 Add "Both infusions ceased at 6 hr" to the legend to Figure 6.3. Page 195 (line 2) "was" should fead "were". Page 198 (line l3) "ro re-€xamine" should read "to te-examine". Pages 245 to29l Bibliosraohv: "8r.." should read "Br.". For the reference by Bhargava et aI. (1991), "J. Pharmacol.Exp.Ther." should read "J. Pharmacol. Exp. Ther." For the reference by Chapman et aI. (1984), a full-stop should appear after"Biomed" . For the reference by Murphey et aI.
    [Show full text]
  • House Bill No. 325
    FIRST REGULAR SESSION HOUSE BILL NO. 325 101ST GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE PRICE IV. 0249H.01I DANA RADEMAN MILLER, Chief Clerk AN ACT To repeal sections 195.010, 579.015, 579.020, 579.040, 579.055, and 579.105, RSMo, and to enact in lieu thereof twenty new sections relating to the legalization of marijuana for adult use, with penalty provisions. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Sections 195.010, 579.015, 579.020, 579.040, 579.055, and 579.105, RSMo, 2 are repealed and twenty new sections enacted in lieu thereof, to be known as sections 195.010, 3 195.2300, 195.2303, 195.2309, 195.2310, 195.2312, 195.2315, 195.2317, 195.2318, 195.2321, 4 195.2324, 195.2327, 195.2330, 195.2333, 579.015, 579.020, 579.040, 579.055, 579.105, and 5 610.134, to read as follows: 195.010. The following words and phrases as used in this chapter and chapter 579, 2 unless the context otherwise requires, mean: 3 (1) "Acute pain", pain, whether resulting from disease, accidental or intentional trauma, 4 or other causes, that the practitioner reasonably expects to last only a short period of time. Acute 5 pain shall not include chronic pain, pain being treated as part of cancer care, hospice or other 6 end-of-life care, or medication-assisted treatment for substance use disorders; 7 (2) "Addict", a person who habitually uses one or more controlled substances to such an 8 extent as to create a tolerance for such drugs, and who does not have a medical need for such 9 drugs, or who is so far addicted to the use of such drugs as to have lost the power of self-control 10 with reference to his or her addiction; 11 (3) "Administer", to apply a controlled substance, whether by injection, inhalation, 12 ingestion, or any other means, directly to the body of a patient or research subject by: 13 (a) A practitioner (or, in his or her presence, by his or her authorized agent); or EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law.
    [Show full text]
  • ECO-Ssls for Pahs
    Ecological Soil Screening Levels for Polycyclic Aromatic Hydrocarbons (PAHs) Interim Final OSWER Directive 9285.7-78 U.S. Environmental Protection Agency Office of Solid Waste and Emergency Response 1200 Pennsylvania Avenue, N.W. Washington, DC 20460 June 2007 This page intentionally left blank TABLE OF CONTENTS 1.0 INTRODUCTION .......................................................1 2.0 SUMMARY OF ECO-SSLs FOR PAHs......................................1 3.0 ECO-SSL FOR TERRESTRIAL PLANTS....................................4 5.0 ECO-SSL FOR AVIAN WILDLIFE.........................................8 6.0 ECO-SSL FOR MAMMALIAN WILDLIFE..................................8 6.1 Mammalian TRV ...................................................8 6.2 Estimation of Dose and Calculation of the Eco-SSL ........................9 7.0 REFERENCES .........................................................16 7.1 General PAH References ............................................16 7.2 References Used for Derivation of Plant and Soil Invertebrate Eco-SSLs ......17 7.3 References Rejected for Use in Derivation of Plant and Soil Invertebrate Eco-SSLs ...............................................................18 7.4 References Used in Derivation of Wildlife TRVs .........................25 7.5 References Rejected for Use in Derivation of Wildlife TRV ................28 i LIST OF TABLES Table 2.1 PAH Eco-SSLs (mg/kg dry weight in soil) ..............................4 Table 3.1 Plant Toxicity Data - PAHs ..........................................5 Table 4.1
    [Show full text]
  • “Biosynthesis of Morphine in Mammals”
    “Biosynthesis of Morphine in Mammals” D i s s e r t a t i o n zur Erlangung des akademischen Grades Doctor rerum naturalium (Dr. rer. nat.) vorgelegt der Naturwissenschaftlichen Fakultät I Biowissenschaften der Martin-Luther-Universität Halle-Wittenberg von Frau Nadja Grobe geb. am 21.08.1981 in Querfurt Gutachter /in 1. 2. 3. Halle (Saale), Table of Contents I INTRODUCTION ........................................................................................................1 II MATERIAL & METHODS ........................................................................................ 10 1 Animal Tissue ....................................................................................................... 10 2 Chemicals and Enzymes ....................................................................................... 10 3 Bacteria and Vectors ............................................................................................ 10 4 Instruments ........................................................................................................... 11 5 Synthesis ................................................................................................................ 12 5.1 Preparation of DOPAL from Epinephrine (according to DUNCAN 1975) ................. 12 5.2 Synthesis of (R)-Norlaudanosoline*HBr ................................................................. 12 5.3 Synthesis of [7D]-Salutaridinol and [7D]-epi-Salutaridinol ..................................... 13 6 Application Experiments .....................................................................................
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Cerebellar Toxicity of Phencyclidine
    The Journal of Neuroscience, March 1995, 75(3): 2097-2108 Cerebellar Toxicity of Phencyclidine Riitta N&kki, Jari Koistinaho, Frank Ft. Sharp, and Stephen M. Sagar Department of Neurology, University of California, and Veterans Affairs Medical Center, San Francisco, California 94121 Phencyclidine (PCP), clizocilpine maleate (MK801), and oth- Phencyclidine (PCP), dizocilpine maleate (MK801), and other er NMDA antagonists are toxic to neurons in the posterior NMDA receptor antagonistshave attracted increasing attention cingulate and retrosplenial cortex. To determine if addition- becauseof their therapeutic potential. These drugs have neuro- al neurons are damaged, the distribution of microglial ac- protective properties in animal studies of focal brain ischemia, tivation and 70 kDa heat shock protein (HSP70) induction where excitotoxicity is proposedto be an important mechanism was studied following the administration of PCP and of neuronal cell death (Dalkara et al., 1990; Martinez-Arizala et MK801 to rats. PCP (10-50 mg/kg) induced microglial ac- al., 1990). Moreover, NMDA antagonists decrease neuronal tivation and neuronal HSP70 mRNA and protein expression damage and dysfunction in other pathological conditions, in- in the posterior cingulate and retrosplenial cortex. In ad- cluding hypoglycemia (Nellgard and Wieloch, 1992) and pro- dition, coronal sections of the cerebellar vermis of PCP (50 longed seizures(Church and Lodge, 1990; Faingold et al., 1993). mg/kg) treated rats contained vertical stripes of activated However, NMDA antagonists are toxic to certain neuronal microglial in the molecular layer. In the sagittal plane, the populations in the brain. Olney et al. (1989) demonstratedthat microglial activation occurred in irregularly shaped patch- the noncompetitive NMDA antagonists,PCP, MK801, and ke- es, suggesting damage to Purkinje cells.
    [Show full text]
  • Potentiation of the Mydriatic Effect of Norepinephrine in the Rabbit After
    Reports Potentiation of the mydriatic effect of change.7 After topical application of the mono- norepinephrine in the rabbit after amine releaser Ro 4-1284 to the eyes of rabbits monoamine oxidase inhibition. BRENDA K. pretreated with these MAO inhibitors, however, COLASANTI AND ERNST H. BARANY. pupillary dilation ensued. As in the case of re- sponses of other peripheral tissues, the response Dose-response curves of pupillary dilation after topical of the iris to indirectly acting sympathomimetic administration of norepinephrine or methoxamine have agents has been shown to be potentiated in hu- been determined in rabbits after chronic inhibition of man subjects undergoing treatment with MAO in- ocular monoamine oxidase by treatment with pargyline hibitors.8 or pheniprazine. Eyes treated with either monoamine ox- In the present communication, we report a idase inhibitor showed an enhanced responsiveness to potentiation of the mydriatic response of the rab- the mydriatic effect of norepinephrine given either topi- bit eye to norepinephrine after prior treatment cally or intravenously. Increments in pupil size of the with MAO inhibitors. This increase in sensitivity treated and control eyes in response to methoxamine applied topically, on the other hand, were the same. of the iris contrasts with the unaltered responses of These results suggest that monoamine oxidase may play a other peripheral organs and tissues to directly act- 2 role in the iris as one factor influencing the concentration ing catecholamines after MAO inhibition. of norepinephrine at the receptors. Methods. Adult male albino rabbits weighing 2 to 3 kg were used in these experiments. Pheni- The principal mechanism for physiological inac- prazine (Draco, Lund and Merrell—National tivation of norepinephrine released from adren- Laboratories, Ohio) was applied topically by mi- ergic nerve endings for action on autonomic effec- crodrop to the right eyes of three groups of six tor organs involves reuptake into the prejunctional rabbits once daily for 7 days.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit
    DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI M.S. in Computational Biology and Bioinformatics, Kadir Has University, 2012 Submitted to the Graduate School of Science and Engineering in partial fulfilment of the requirements for the degree of Master of Science in Computational Biology and Bioinformatics KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B Abstract In drug development studies, a large number of new drug candidates (leads) have to be synthesized and optimized by changing several moieties of the leads in order to increase efficacies and decrease toxicities. Each synthesis of these new drug candidates include multi-steps procedures. Overall, discovering a new drug is a very time-consuming and very costly works. The development of molecular modelling programs and their applications in pharmaceutical research have been formalized as a field of study known computer assisted drug design (CADD) or computer assisted molecular design (CAMD). In this study, using the above techniques, Monoamine Oxidase isozymes, which play an essential role in the oxidative deamination of the biogenic amines, were studied. Compounds that inhibit these isozymes were shown to have therapeutic value in a variety of conditions including several psychiatric and neurological as well as neurodegenerative diseases. First, a series of new pyrazoline derivatives were screened using molecular modelling and docking methods and promising lead compounds were selected, and proposed for synthesis as novel selective MAO-A or –B inhibitors.
    [Show full text]
  • Self-Administration of Abused Substances: Methods for Study
    Self-Administration of Abused Substances: Methods for Study U.S. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Self-Administration of Abused Substances: Methods for Study Editor: Norman A. Krasnegor, Ph.D. NIDA Research Monograph 20 July 1978 DEPARTMENT OF HEALTH. EDUCATION, AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, D.C. 20402 Stock No. 017-024-00794-3 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical re- views of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Polo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Department of Psychology. UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHEW Washington, D C Lee Robins, Ph.D. Washington University School of Medicine St Louis, Missouri NIDA Research Monograph series William Pollin, M.D.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]